News Detail

Shanghai's H1 Tax Cuts, Fee Reductions and Rebates for Tech Innovation Top 140 Billion Yuan

In the first half of 2026, Shanghai's tax cuts, fee reductions and rebates under major policies supporting sci-tech innovation and manufacturing exceeded 140 billion yuan, aiding R&D, technology breakthroughs and industrial upgrading. Advanced manufacturing VAT credits and similar policies accounted for over 53 billion yuan; R&D expense super-deductions and technology transfer policies over 73 billion yuan; and the 15% preferential corporate income tax rate for high-tech firms about 17 billion yuan. Firms in laser weeding robots, domestic semiconductor testing equipment and innovative drugs said the support effectively freed up cash flow and eased R&D funding pressure, and that they will keep improving tax compliance management.

Industry News国家税务总局上海市税务局Source
2026-10-02

In the first half of 2026, Shanghai's tax cuts, fee reductions and rebates under major policies supporting sci-tech innovation and manufacturing development exceeded 140 billion yuan, helping enterprises with innovative R&D, technology breakthroughs and industrial upgrading. Data shows that in the first half, policies such as VAT additional credits for advanced manufacturing enterprises, which help break through bottlenecks and support high-end development, accounted for over 53 billion yuan in tax and fee reductions. Weilan Engine (Shanghai) Technology Co., Ltd. in Jiading District launched the 'Guangyun' series, the first domestically commercialized laser weeding robot, successfully opening domestic and overseas markets; its founder Zhao Zhiwu said the firm enjoyed over 4.2 million yuan in R&D expense super-deduction in the first half, easing funding pressure. Shengdake Semiconductor Technology (Shanghai) Co., Ltd. in Qingpu District, a national 'little giant' specialized in domestic semiconductor testing equipment, saw revenue grow over 70% year on year with nearly 20 million yuan in R&D super-deduction. Data shows R&D super-deduction and technology transfer policies accounted for over 73 billion yuan; Shanghai Allist Pharmaceuticals, an innovative drug firm, enjoyed over 129 million yuan in corporate income tax relief. Policies such as the 15% preferential rate for high-tech enterprises accounted for about 17 billion yuan. The tax authority said it will continue standardizing policy implementation and delivering benefits precisely to market entities.